0	8	Retinoic	retinoic	JJ
9	13	acid	acid	NN
14	22	inhibits	inhibit	VBZ
23	27	CD40	CD40	NNP
28	29	+	+	SYM
30	52	interleukin-4-mediated	interleukin-4-mediated	JJ
53	56	IgE	ige	NN
57	67	production	production	NN
68	70	in	in	FW
71	76	vitro	vitro	FW
76	77	.	.	.

79	81	To	to	TO
82	91	elucidate	elucidate	VB
92	95	the	the	DT
96	100	role	role	NN
101	103	of	of	IN
104	112	retinoic	retinoic	JJ
113	117	acid	acid	NN
118	119	(	(	(
119	121	RA	RA	NNP
121	122	)	)	)
123	125	in	in	IN
126	135	anti-CD40	anti-cd40	NN
136	137	+	+	SYM
138	151	interleukin-4	interleukin-4	NN
152	153	(	(	(
153	167	IL-4)-mediated	il-4)-mediated	JJ
168	174	B-cell	B-cell	NNP
175	185	activation	activation	NN
185	186	,	,	,
187	190	the	the	DT
191	197	effect	effect	NN
198	200	of	of	IN
201	208	10(-12)	10(-12)	CD
209	211	to	to	TO
212	218	10(-6)	10(-6)	CD
219	224	mol/L	mol/l	NN
225	227	RA	RA	NNP
228	231	was	be	VBD
232	239	studied	study	VBN
240	242	in	in	IN
243	252	anti-CD40	anti-cd40	NN
253	254	(	(	(
254	255	1	1	CD
256	268	microgram/mL	microgram/ml	NN
268	269	)	)	)
270	271	+	+	CC
272	276	IL-4	il-4	NN
277	278	(	(	(
278	279	5	5	CD
280	295	ng/mL)-mediated	ng/ml)-mediated	JJ
296	309	proliferation	proliferation	NN
310	313	and	and	CC
314	316	Ig	ig	NN
317	326	synthesis	synthesis	NN
327	329	by	by	IN
330	335	human	human	JJ
336	346	peripheral	peripheral	JJ
347	352	blood	blood	NN
353	364	mononuclear	mononuclear	JJ
365	370	cells	cell	NNS
371	372	(	(	(
372	376	PBMC	PBMC	NNP
376	377	)	)	)
378	381	and	and	CC
382	383	B	B	NNP
384	389	cells	cell	NNS
390	392	in	in	IN
393	400	healthy	healthy	JJ
401	407	donors	donor	NNS
407	408	.	.	.

409	418	Anti-CD40	Anti-CD40	NNP
419	420	+	+	CC
421	434	IL-4-mediated	il-4-mediated	JJ
435	448	proliferation	proliferation	NN
449	451	of	of	IN
452	456	PBMC	PBMC	NNP
457	460	and	and	CC
461	462	B	B	NNP
463	468	cells	cell	NNS
469	472	was	be	VBD
473	482	inhibited	inhibit	VBN
483	485	by	by	IN
486	488	RA	RA	NNP
489	491	in	in	IN
492	493	a	a	DT
494	508	dose-dependent	dose-dependent	JJ
509	515	manner	manner	NN
515	516	,	,	,
517	521	with	with	IN
522	529	maximal	maximal	JJ
530	540	inhibition	inhibition	NN
541	543	of	of	IN
544	546	62	62	CD
546	547	%	%	NN
548	551	+/-	+/-	SYM
552	553	5	5	CD
553	554	%	%	NN
555	557	in	in	IN
558	562	PBMC	PBMC	NNP
563	566	and	and	CC
567	569	55	55	CD
569	570	%	%	NN
571	574	+/-	+/-	SYM
575	578	4.4	4.4	CD
578	579	%	%	NN
580	582	in	in	IN
583	584	B	B	NNP
585	590	cells	cell	NNS
591	593	by	by	IN
594	603	all-trans	all-trans	JJ
604	606	RA	RA	NNP
606	607	,	,	,
608	611	and	and	CC
612	614	58	58	CD
614	615	%	%	NN
616	619	+/-	+/-	SYM
620	623	6.7	6.7	CD
623	624	%	%	NN
625	628	and	and	CC
629	631	51	51	CD
631	632	%	%	NN
633	636	+/-	+/-	SYM
637	640	4.7	4.7	CD
640	641	%	%	NN
641	642	,	,	,
643	655	respectively	respectively	RB
656	658	by	by	IN
659	665	13-cis	13-cis	JJ
666	668	RA	RA	NNP
668	669	.	.	.

670	673	IgE	IgE	NNP
674	683	synthesis	synthesis	NN
684	687	was	be	VBD
688	692	even	even	RB
693	697	more	more	RBR
698	706	markedly	markedly	RB
707	716	inhibited	inhibit	VBN
717	719	by	by	IN
720	722	RA	RA	NNP
723	731	starting	start	VBG
732	734	at	at	IN
735	749	concentrations	concentration	NNS
750	752	of	of	IN
753	761	>10(-14)	>10(-14)	JJ
762	767	mol/L	mol/l	NN
768	771	for	for	IN
772	773	B	B	NNP
774	779	cells	cell	NNS
780	783	and	and	CC
784	792	>10(-10)	>10(-10)	JJ
793	798	mol/L	mol/l	NN
799	802	for	for	IN
803	807	PBMC	PBMC	NNP
807	808	.	.	.

809	816	Maximal	maximal	JJ
817	827	inhibition	inhibition	NN
828	830	of	of	IN
831	834	IgE	ige	NN
835	845	production	production	NN
846	849	for	for	IN
850	851	B	B	NNP
852	857	cells	cell	NNS
858	861	was	be	VBD
862	864	at	at	IN
865	871	10(-8)	10(-8)	CD
872	877	mol/L	mol/l	NN
878	881	for	for	IN
882	891	all-trans	all-trans	JJ
892	894	RA	RA	NNP
895	896	(	(	(
896	898	94	94	CD
898	899	%	%	NN
900	903	+/-	+/-	SYM
904	907	1.8	1.8	CD
907	908	%	%	NN
908	909	)	)	)
910	913	and	and	CC
914	916	96	96	CD
916	917	%	%	NN
918	921	+/-	+/-	SYM
922	925	3.2	3.2	CD
925	926	%	%	NN
927	930	for	for	IN
931	937	13-cis	13-cis	JJ
938	940	RA	RA	NNP
940	941	.	.	.

942	945	Low	low	JJ
946	960	concentrations	concentration	NNS
961	963	of	of	IN
964	966	RA	RA	NNP
967	977	inhibiting	inhibit	VBG
978	981	IgE	ige	NN
982	991	synthesis	synthesis	NN
992	993	(	(	(
993	1000	10(-10)	10(-10)	CD
1001	1006	mol/L	mol/l	NN
1006	1007	)	)	)
1008	1016	affected	affect	VBD
1017	1024	neither	neither	CC
1025	1031	B-cell	b-cell	NN
1032	1045	proliferation	proliferation	NN
1046	1049	nor	nor	CC
1050	1053	the	the	DT
1054	1064	production	production	NN
1065	1067	of	of	IN
1068	1071	IgA	IgA	NNP
1071	1072	,	,	,
1073	1076	IgG	IgG	NNP
1076	1077	,	,	,
1078	1081	and	and	CC
1082	1085	IgM	IgM	NNP
1085	1086	.	.	.

1087	1098	Elucidation	elucidation	NN
1099	1101	of	of	IN
1102	1105	the	the	DT
1106	1115	mechanism	mechanism	NN
1116	1124	involved	involve	VBN
1125	1127	in	in	IN
1128	1132	this	this	DT
1133	1143	inhibition	inhibition	NN
1144	1146	of	of	IN
1147	1150	IgE	IgE	NNP
1151	1161	production	production	NN
1162	1167	shows	show	VBZ
1168	1172	that	that	IN
1173	1180	epsilon	epsilon	NN
1181	1189	germline	germline	NN
1190	1203	transcription	transcription	NN
1204	1206	is	be	VBZ
1207	1216	decreased	decrease	VBN
1217	1219	by	by	IN
1220	1222	RA	RA	NNP
1222	1223	,	,	,
1224	1231	whereas	whereas	IN
1232	1242	production	production	NN
1243	1245	of	of	IN
1246	1262	interferon-gamma	interferon-gamma	NN
1263	1264	(	(	(
1264	1273	IFN-gamma	IFN-gamma	NNP
1273	1274	)	)	)
1275	1278	was	be	VBD
1279	1282	not	not	RB
1283	1291	enhanced	enhance	VBN
1292	1294	in	in	IN
1295	1298	the	the	DT
1299	1307	presence	presence	NN
1308	1310	of	of	IN
1311	1313	RA	RA	NNP
1313	1314	.	.	.

1315	1317	To	to	TO
1318	1331	differentiate	differentiate	VB
1332	1339	whether	whether	IN
1340	1343	the	the	DT
1344	1346	RA	RA	NNP
1347	1353	effect	effect	NN
1354	1357	was	be	VBD
1358	1366	mediated	mediate	VBN
1367	1369	by	by	IN
1370	1372	RA	RA	NNP
1373	1382	receptors	receptor	NNS
1383	1388	alpha	alpha	NN
1388	1389	,	,	,
1390	1394	beta	beta	NN
1394	1395	,	,	,
1396	1399	and	and	CC
1400	1405	gamma	gamma	NN
1405	1406	,	,	,
1407	1410	the	the	DT
1411	1421	expression	expression	NN
1422	1424	of	of	IN
1425	1428	the	the	DT
1429	1437	retinoic	retinoic	JJ
1438	1442	acid	acid	NN
1443	1452	receptors	receptor	NNS
1453	1454	(	(	(
1454	1457	RAR	RAR	NNP
1457	1458	)	)	)
1459	1462	was	be	VBD
1463	1471	examined	examine	VBN
1472	1474	by	by	IN
1475	1482	reverse	reverse	JJ
1483	1507	transcriptase-polymerase	transcriptase-polymerase	NN
1508	1513	chain	chain	NN
1514	1522	reaction	reaction	NN
1523	1524	(	(	(
1524	1530	RT-PCR	RT-PCR	NNP
1530	1531	)	)	)
1531	1532	.	.	.

1533	1536	The	the	DT
1537	1541	data	datum	NNS
1542	1546	show	show	VBP
1547	1551	that	that	IN
1552	1564	unstimulated	unstimulated	JJ
1565	1570	human	human	JJ
1571	1581	peripheral	peripheral	JJ
1582	1583	B	B	NNP
1584	1589	cells	cell	NNS
1590	1597	express	express	VBP
1598	1602	mRNA	mrna	NN
1603	1605	of	of	IN
1606	1609	the	the	DT
1610	1612	RA	RA	NNP
1613	1621	receptor	receptor	NN
1622	1627	alpha	alpha	NN
1627	1628	,	,	,
1629	1633	beta	beta	NN
1633	1634	,	,	,
1635	1638	and	and	CC
1639	1644	gamma	gamma	NN
1644	1645	.	.	.

1646	1651	Using	use	VBG
1652	1661	retinoids	retinoid	NNS
1662	1666	with	with	IN
1667	1676	different	different	JJ
1677	1685	receptor	receptor	NN
1686	1693	binding	binding	NN
1694	1705	specificity	specificity	NN
1706	1707	(	(	(
1707	1712	CD336	CD336	NNP
1712	1713	,	,	,
1714	1719	CD437	CD437	NNP
1719	1720	,	,	,
1721	1727	CD2019	CD2019	NNP
1727	1728	,	,	,
1729	1734	CD367	CD367	NNP
1734	1735	)	)	)
1735	1736	,	,	,
1737	1751	dose-dependent	dose-dependent	JJ
1752	1762	inhibition	inhibition	NN
1763	1765	of	of	IN
1766	1769	IgE	IgE	NNP
1770	1779	synthesis	synthesis	NN
1780	1783	was	be	VBD
1784	1789	shown	show	VBN
1790	1792	by	by	IN
1793	1796	all	all	DT
1797	1801	four	four	CD
1802	1811	derivates	derivate	NNS
1811	1812	,	,	,
1813	1816	but	but	CC
1817	1820	was	be	VBD
1821	1825	most	most	RBS
1826	1832	marked	mark	VBN
1833	1835	by	by	IN
1836	1838	an	an	DT
1839	1841	RA	RA	NNP
1842	1849	binding	bind	VBG
1850	1853	the	the	DT
1854	1859	alpha	alpha	NN
1860	1868	receptor	receptor	NN
1869	1873	with	with	IN
1874	1878	high	high	JJ
1879	1890	specificity	specificity	NN
1890	1891	.	.	.

1892	1897	Taken	take	VBN
1898	1906	together	together	RB
1906	1907	,	,	,
1908	1912	this	this	DT
1913	1918	study	study	NN
1919	1924	shows	show	VBZ
1925	1929	that	that	IN
1930	1932	RA	RA	NNP
1933	1941	inhibits	inhibit	VBZ
1942	1945	IgE	ige	NN
1946	1956	production	production	NN
1957	1959	of	of	IN
1960	1969	anti-CD40	anti-cd40	JJ
1970	1971	+	+	CC
1972	1987	IL-4-stimulated	il-4-stimulated	JJ
1988	1989	B	B	NNP
1990	1995	cells	cell	NNS
1996	1998	in	in	FW
1999	2004	vitro	vitro	FW
2004	2005	.	.	.

2006	2015	Copyright	Copyright	NNP
2016	2020	1998	1998	CD
2021	2023	by	by	IN
2024	2027	The	The	NNP
2028	2036	American	American	NNP
2037	2044	Society	Society	NNP
2045	2047	of	of	IN
2048	2058	Hematology	Hematology	NNP
2058	2059	.	.	.